1
Open
[.]
2
Close
[.]
3
Allotment
—
4
Listing
[.]
Listing Date
[.]
✦ AI Insight
Restated Financials (₹ Cr.)
| Period Ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 246.30 | 224.65 | 186.68 | 124.02 |
| Total Income | 78.53 | 138.07 | 106.03 | 109.42 |
| Profit After Tax | 10.89 | 23.41 | 17.99 | 14.14 |
| NET Worth | 90.74 | 79.89 | 56.49 | 38.58 |
| Reserves and Surplus | 86.49 | 75.64 | 52.24 | 35.08 |
| Total Borrowing | 106.90 | 104.97 | 97.17 | 49.53 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Hexagon Nutrition Ltd. | Mainboard | ₹138.87 Cr | ₹45 | 22.69 | ₹53.19 | +18.20% | ₹65.51 (+1.93%) |
| Sai Parenteral's Ltd. | Mainboard | ₹408.79 Cr | ₹392 | 72.19 | ₹405.70 | +3.49% | ₹535.60 (-0.34%) |
| Corona Remedies Ltd. | Mainboard | ₹655.37 Cr | ₹1062 | 43.47 | ₹1,438.40 | +35.44% | ₹2,113.00 (+4.28%) |
| Rubicon Research Ltd. | Mainboard | ₹1,377.50 Cr | ₹485 | 55.75 | ₹628.20 | +29.53% | ₹1,520.20 (-0.78%) |
| Amanta Healthcare Ltd. | Mainboard | ₹126.00 Cr | ₹126 | 34.59 | ₹141.75 | +12.50% | ₹163.00 (-0.61%) |
| Anlon Healthcare Ltd. | Mainboard | ₹121.03 Cr | ₹91 | 17.67 | ₹91.73 | +0.80% | ₹15.01 (-0.40%) |
| Bio Medica Laboratories Ltd. | SME | ₹52.43 Cr | ₹139 | 13.03 | ₹115.80 | -16.69% | ₹138.70 (-0.18%) |
| Goldline Pharmaceutical Ltd. | SME | ₹11.61 Cr | ₹43 | 10.47 | ₹56.77 | +32.02% | ₹38.13 (-4.65%) |
| Speciality Medicines Ltd. | SME | ₹29.14 Cr | ₹124 | 9.27 | ₹125.90 | +1.53% | ₹185.00 (+0.00%) |
| Accretion Nutraveda Ltd. | SME | ₹24.77 Cr | ₹129 | 26.27 | ₹191.20 | +48.22% | ₹273.75 (+0.09%) |
| KRM Ayurveda Ltd. | SME | ₹77.49 Cr | ₹135 | 17.32 | ₹180.70 | +33.85% | ₹255.30 (+2.51%) |
| Curis Lifesciences Ltd. | SME | ₹27.52 Cr | ₹128 | 12.44 | ₹141.00 | +10.16% | ₹112.00 (+1.82%) |
| Aptus Pharma Ltd. | SME | ₹13.02 Cr | ₹70 | 11.29 | ₹84.84 | +21.20% | ₹254.50 (+1.13%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Repayment or pre-payment, in full or in part, of certain of the outstanding borrowings availed by the Company. | 130.00 |
| 2 | General Corporate Purposes | |
| Total | 130.00 |
About Allchem Lifescience IPO
Incorporated in 2017, Allchem Lifescience Limited is manufacturer of active pharmaceutical ingredient (API) intermediates and specialty chemicals. The company focuses on producing key starting materials (KSMs), generic API intermediates, and speciality chemicals to cater to both domestic and international pharmaceutical and chemical industries. Business Verticals Allchem Lifescience Limited operates through two primary business segments: Manufacturing API Intermediates API intermediates are essential chemical compoundsused in the production of active pharmaceutical ingredients (APIs) and finished drugs. These intermediates serve as crucial building blocks in synthesis processes, undergoing transformations that result in the final API or drug formulation. Specialty or Fine Chemicals Specialty chemicals, also known as performance chemicals, are custom-designed substances for specific applications. Product Portfolio & Capabilities Allchem Lifescience Limited has developed the capability to manufacture 263 products, demonstrating expertise in various organic chemical compounds and advanced chemistries. Clientele The company serves a diverse range of domestic and international customers
Contact Details
Allchem Lifescience Ltd. AddressBlock No. 1088/B/P, 1088-A, Lamdapura Road,Village Manjusar,Tal-SavliVadodara, Gujarat, 391775+91-9574722211investor@allchemlifescience.comVisit Website